Advertisement

Clinical and Translational Oncology

, Volume 17, Issue 10, pp 763–771 | Cite as

Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology

  • A. GodayEmail author
  • I. Barneto
  • J. M. García-Almeida
  • A. Blasco
  • A. Lecube
  • C. Grávalos
  • P. Martínez de Icaya
  • R. de las Peñas
  • S. Monereo
  • L. Vázquez
  • J. E. Palacio
  • P. Pérez-Segura
Special Article

Abstract

In the last few years, many prospective studies have demonstrated a clear association between obesity and cancers of the colon and rectum, breast in post-menopausal women, endometrium, kidney, oesophagus and pancreas. Obesity is also associated with a high risk of recurrence and cancer-related death. The pathophysiology of obesity involves various changes that may be implicated in the relationship between obesity and cancer, such as excess inflammatory cytokines and chronic inflammation, hyperinsulinaemia, insulin resistance, and raised leptin and oestrogens. The Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology have signed a cooperation agreement to work together towards reducing the impact of obesity in cancer. Preventing obesity prevents cancer.

Keywords

Fatty acids Adipokines Inflammatory cytokines IGF1 and 2 BMI Insulin 

Notes

Acknowledgments

The authors are grateful for the editorial assistance of Ana Martín of HealthCo (Madrid, Spain) in the production of this manuscript.

Conflict of interest

The authors declare that, when writing and revising the text, they did not know the names of the pharmaceutical companies that provided financial support for this project, so this support has not influenced the content of this article.

Ethical statement

The study has been performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent statement

Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

References

  1. 1.
    WHO World Health Statistics. Geneva: World Health Organization; 2014. http://apps.who.int/iris/bitstream/10665/112738/1/9789240692671_eng.pdf
  2. 2.
    Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Recomendaciones nutricionales basadas en la evidencia para la prevención y el tratamiento del sobrepeso y la obesidad en adultos (Consenso FESNAD-SEEDO). Rev Esp Obes. 2011; 10 Suppl 1.http://www.seedo.es/images/site/documentacionConsenso/Guia_obesidad_SEEN_Endocrinologia_2003.pdf.
  5. 5.
    Berghöfer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008;8:200.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    González SCA, Goday AA. Obesidad y cáncer : “las amistades peligrosas”. Med Clin (Barc). 2014. Available at: http://dx.doi.org/10.1016/j.medcli.2014.05.026. Accessed Dec 2014.
  7. 7.
    Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755–65.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, et al. American society of clinical oncology position statement on obesity and cancer. J Clin Oncol. 2014;32:3568–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Rubio Miguel A, Salas-Salvadó Jordi, Barbany Montserrat, Moreno Basilio, Aranceta Javier, Bellido D, et al. Consenso SEEDO 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica (versión íntegra). Rev Esp Obes. 2007; 7–48. http://www.seedo.es/images/site/documentacionConsenso/Consenso_SEEDO_2007.pdf.Google Scholar
  10. 10.
    Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, et al. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20:977–89.CrossRefPubMedGoogle Scholar
  11. 11.
    Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Gutierrez-Fisac JL, Guallar-Castillon P, Leon-Munoz LM, Graciani A, Banegas JR, Rodriguez-Artalejo F. Prevalence of general and abdominal obesity in the adult population of Spain, 2008-2010: the ENRICA study. Obes Rev. 2012;13:388–92.CrossRefPubMedGoogle Scholar
  13. 13.
    Gomez-Ambrosi J, Silva C, Galofre JC, Escalada J, Santos S, Millan D, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond). 2012;36:286–94.CrossRefGoogle Scholar
  14. 14.
    Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11:886–95.CrossRefPubMedGoogle Scholar
  16. 16.
    Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, Mannel DN. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med. 1993;177:1391–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98:295–303.CrossRefPubMedGoogle Scholar
  18. 18.
    Nkhata KJ, Ray A, Schuster TF, Grossmann ME, Cleary MP. Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep. 2009;21:1611–9.PubMedGoogle Scholar
  19. 19.
    Fusco R, Galgani M, Procaccini C, Franco R, Pirozzi G, Fucci L, et al. Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat Cancer. 2010;17:373–82.CrossRefPubMedGoogle Scholar
  20. 20.
    Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004;4:604–16.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang Y, Bellows CF, Kolonin MG. Adipose tissue-derived progenitor cells and cancer. World J Stem Cells. 2010;2:103–13.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila). 2011;4:1021–9.CrossRefGoogle Scholar
  23. 23.
    Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222–5.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA. 1994;91:6379–83.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene. 2005;24:39–46.CrossRefPubMedGoogle Scholar
  27. 27.
    Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140:49–61.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Li YC, Park MJ, Ye SK, Kim CW, Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006;168:1107–18 quiz 404–5.CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Tilg H, Moschen AR. Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract Res Clin Gastroenterol. 2014;28:599–610.CrossRefPubMedGoogle Scholar
  30. 30.
    Shirakami Y, Shimizu M, Kubota M, Araki H, Tanaka T, Moriwaki H, et al. Chemoprevention of colorectal cancer by targeting obesity-related metabolic abnormalities. World J Gastroenterol. 2014;20:8939–46.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Lin XJ, Wang CP, Liu XD, Yan KK, Li S, Bao HH, et al. Body mass index and risk of gastric cancer: a meta-analysis. Jpn J Clin Oncol. 2014;44:783–91.CrossRefPubMedGoogle Scholar
  32. 32.
    Kasenda B, Bass A, Koeberle D, Pestalozzi B, Borner M, Herrmann R, et al. Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study. BMC Cancer. 2014;14:728.CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Scarpa M, Ruffolo C, Erroi F, Fiorot A, Basato S, Pozza A, et al. Obesity is a risk factor for multifocal disease and recurrence after colorectal cancer surgery: a case-control study. Anticancer Res. 2014;34:5735–41.PubMedGoogle Scholar
  34. 34.
    Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB 3rd, Macdonald JS, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98:484–95.CrossRefPubMedGoogle Scholar
  35. 35.
    Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, et al. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012;30:406–12.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134.CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Doll KM, Kalinowski AK, Snavely AC, Irwin DE, Bensen JT, Bae-Jump VL, et al. Obesity is associated with worse quality of life in women with gynecologic malignancies: an opportunity to improve patient-centered outcomes. Cancer. 2015;121:395–402. doi: 10.1002/cncr.29061.CrossRefPubMedGoogle Scholar
  38. 38.
    Dossus L, Rinaldi S, Becker S, Lukanova A, Tjonneland A, Olsen A, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer. 2010;17:1007–19.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Lahmann PH, Cust AE, Friedenreich CM, Schulz M, Lukanova A, Kaaks R, et al. Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;126:2404–15.PubMedGoogle Scholar
  40. 40.
    Schouten LJ, Rivera C, Hunter DJ, Spiegelman D, Adami HO, Arslan A, et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev. 2008;17:902–12.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Martin-Ramiro JJ, Alvarez-Martin E, Gil-Prieto R. Mortality attributable to excess weight in Spain. Med Clin (Barc). 2014;142:526–30.CrossRefGoogle Scholar
  42. 42.
    Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25:1901–14.CrossRefPubMedCentralPubMedGoogle Scholar
  43. 43.
    Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer—mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10:455–65.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, et al. Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol. 2005;23:6037–42.CrossRefPubMedGoogle Scholar
  45. 45.
    Advani P, Moreno-Aspitia A. Current strategies for the prevention of breast cancer. Breast Cancer (Dove Med Press). 2014;6:59–71.Google Scholar
  46. 46.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.CrossRefPubMedGoogle Scholar
  47. 47.
    Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.CrossRefPubMedGoogle Scholar
  48. 48.
    Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305–11.CrossRefPubMedGoogle Scholar
  49. 49.
    Zigeuner R. Editorial comment on: lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol. 2008;54:873–4.CrossRefPubMedGoogle Scholar
  50. 50.
    Buschemeyer WC 3rd, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007;52:331–43.CrossRefPubMedGoogle Scholar
  51. 51.
    Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol. 2007;52:46–53.CrossRefPubMedGoogle Scholar
  52. 52.
    Ribeiro R, Monteiro C, Catalan V, Hu P, Cunha V, Rodriguez A, et al. Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue. BMC Med. 2012;10:108.CrossRefPubMedCentralPubMedGoogle Scholar
  53. 53.
    Pruthi RS, Swords K, Schultz H, Carson CC 3rd, Wallen EM. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. J Urol. 2009;181:574–7 discussion 8.CrossRefPubMedGoogle Scholar
  54. 54.
    Motamedinia P, Korets R, Spencer BA, Benson MC, McKiernan JM. Body mass index trends and role of obesity in predicting outcome after radical prostatectomy. Urology. 2008;72:1106–10.CrossRefPubMedGoogle Scholar
  55. 55.
    Koebnick C, Michaud D, Moore SC, Park Y, Hollenbeck A, Ballard-Barbash R, et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2008;17:1214–21.CrossRefPubMedGoogle Scholar
  56. 56.
    Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, Wu X. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol. 2003;169:714–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Hilmy M, Bartlett JM, Underwood MA, McMillan DC. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer. 2005;92:625–7.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, et al. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer. 2013;132:1162–9.CrossRefPubMedGoogle Scholar
  59. 59.
    Zhao ZG, Guo XG, Ba CX, Wang W, Yang YY, Wang J, et al. Overweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. J Int Med Res. 2012;40:2041–50.CrossRefPubMedGoogle Scholar
  60. 60.
    Larsson SC, Wolk A. Obesity and risk of non-Hodgkin’s lymphoma: a meta-analysis. Int J Cancer. 2007;121:1564–70.CrossRefPubMedGoogle Scholar
  61. 61.
    Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, et al. Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study). Br J Cancer. 2013;109:289–94.CrossRefPubMedCentralPubMedGoogle Scholar
  62. 62.
    Khan N, Afaq F, Mukhtar H. Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett. 2010;293:133–43.CrossRefPubMedCentralPubMedGoogle Scholar
  63. 63.
    Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI, et al. Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1803–11.CrossRefPubMedGoogle Scholar
  64. 64.
    Thygesen LC, Gronbaek M, Johansen C, Fuchs CS, Willett WC, Giovannucci E. Prospective weight change and colon cancer risk in male US health professionals. Int J Cancer. 2008;123:1160–5.CrossRefPubMedCentralPubMedGoogle Scholar
  65. 65.
    Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:815–40.CrossRefPubMedCentralPubMedGoogle Scholar
  66. 66.
    Goodwin PJ, Segal RJ, Vallis M, Ligibel JA, Pond GR, Robidoux A, et al. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. J Clin Oncol. 2014;32:2231–9.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2015

Authors and Affiliations

  • A. Goday
    • 1
    • 2
    Email author
  • I. Barneto
    • 3
  • J. M. García-Almeida
    • 4
  • A. Blasco
    • 5
  • A. Lecube
    • 6
  • C. Grávalos
    • 7
  • P. Martínez de Icaya
    • 8
  • R. de las Peñas
    • 9
  • S. Monereo
    • 10
  • L. Vázquez
    • 11
  • J. E. Palacio
    • 12
  • P. Pérez-Segura
    • 13
  1. 1.Servicio de EndocrinologíaHospital del MarBarcelonaSpain
  2. 2.IMIM Institut Mar de Investigacions Mediques, CiberOBNBarcelonaSpain
  3. 3.Servicio de Oncología MédicaHospital Universitario Reina SofíaCórdobaSpain
  4. 4.Servicio de EndocrinologíaHospital Universitario Virgen de la VictoriaMálagaSpain
  5. 5.Servicio de Oncología MédicaConsorcio Hospital General Universitario de ValenciaValenciaSpain
  6. 6.Servicio de EndocrinologíaHospital Arnau de VilanovaLleidaSpain
  7. 7.Servicio de Oncología MédicaHospital Universitario 12 de OctubreMadridSpain
  8. 8.Servicio de EndocrinologíaHospital Universitario Severo OchoaMadridSpain
  9. 9.Servicio de Oncología MédicaConsorcio Hospitalario Provincial de CastellónCastelló de la PlanaSpain
  10. 10.Servicio de EndocrinologíaHospital General Universitario Gregorio MarañónMadridSpain
  11. 11.Servicio de Oncología MédicaComplejo Hospitalario de PontevedraPontevedraSpain
  12. 12.Servicio de EndocrinologíaHospital Universitario Nuestra Señora de CandelariaSanta Cruz de TenerifeSpain
  13. 13.Servicio de Oncología MédicaHospital Clínico Universitario San CarlosMadridSpain

Personalised recommendations